Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — ShareCafe Small Cap "Hidden Gems" Webinar (December 2021)

13 slides from Neuroscientific Biopharmaceuticals's conference presentation, Dec 3, 2021

  1. Slide 1: ASX Announcement: Investor Webinar Presentation

    ASX ANNOUNCEMENT 3 DECEMBER 2021 INVESTOR WEBINAR PRESENTATION For personal use only NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) (“NeuroScientific” or “the Company”) is pleased to announce its participation in the ShareCafe Small Cap “Hidden Gems” Webinar, to be held Friday 3rd December 2021 fr

  2. Slide 2: About EmtinB

    (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinBTM. For more information, please visit www.neuroscientific.com About EmtinBTM EmtinBTM is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular

  3. Slide 3: Novel Drug Therapies for Neurodegenerative Conditions

    NOVEL DRUG THERAPIES FOR N E U R O D E G E N E R AT I V E For personal use only CONDITIONS Company Presentation December 2021

  4. Slide 4: Disclaimer

    DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  5. Slide 5: Company Snapshot

    COMPANY SNAPSHOT For personal use only  EmtinB™ - potential first in-class therapeutic for neurodegenerative conditions NOVEL LEAD COMPOUND  Potential disease modifying therapeutic  Low potential for off-target effects  >40 studies completed to date SUBSTANTIAL SAFETY &  Preclinical efficacy da

  6. Slide 6: Corporate Overview

    CORPORATE OVERVIEW (ASX: NSB) For personal use only CAPITAL STRUCTURE FINANCIALS ASX code NSB  IPO on ASX July 2018 (ASX: NSB) Shares on issue 143.5M  ~ $12.3M cash on hand Price (02/12/21) $0.35 Market cap $50M  Funded through to completion of current Phase I clinical program McRae Investments 1

  7. Slide 7: Leadership and Management

    LEADERSHIP AND MANAGEMENT For personal use only PAUL RENNIE, MBM, MSTC MATT LIDDELOW, MPHARM DR ANTON UVAROV, PhD, MBA STEPHEN QUANTRILL, MBA NON-EXECUTIVE CHAIRMAN MD + CEO EXECUTIVE DIRECTOR + CSO NON-EXECUTIVE DIRECTOR Founding CEO of Paradigm 14+ years experience commercialising Founding directo

  8. Slide 8: Markets

    MARKETS For personal use only  Neurodegenerative Disease market valued at ~USD 39.24 billion in 2020 is expected to witness a revenue of USD 44.90 billion in 20261  ~ 55 million people worldwide currently have dementia; Alzheimer’s disease affects about 60-70% of them2  The global Multiple Sclero

  9. Slide 9: EmtinB Preclinical Data

    EMTINBTM PRECLINICAL DATA For personal use only  Nerve regeneration (including significant results in spinal injury model)  Reduction in neuroinflammation  Neuroprotection in cell survival models >90%  Proliferation of myelin in Multiple Sclerosis model  Slowed cognitive decline in Alzheimer’s

  10. Slide 10: EmtinB Development Plan

    EMTINBTM DEVELOPMENT PLAN For personal use only 2021 2022 Completion of Ph1 neurology Ph2 Neurology study neurology IND-enabling study Q4 2022 studies Q1 2022 Q4 2021 Complete ocular Ph1 glaucoma IND-enabling studies study Q1 2022 H1 2022 Please note: Indicative timeline only and subject to change d

  11. Slide 11: Partners and Collaborations

    PARTNERS AND COLLABORATIONS For personal use only NON-CLINICAL RESEARCH CLINICAL RESEARCH MANUFACTURING SCIENTIFIC ADVISORY Dr Frank Bonner, PhD FBTS Clin Prof. Allan Kermode MBBS MD FRACP FRCP Dr Peter Hnik, MD MHSc Former Director, Non-clinical R&D, Novartis Head, Neurology & Neurophysiology, SCG

  12. Slide 12: Summary Overview

    SUMMARY OVERVIEW For personal use only  Drug development company with advanced preclinical lead candidate - EmtinB™  Funded through to completion of Phase I program  Potential for multiple treatment indications (pipeline in a product)  Peptide based drug with advanced safety program  Transition

  13. Slide 13: For More Information

    F O R M O R E I N F O R M AT I O N : For personal use only Matt Liddelow CEO & Managing Director ml@neuroscientific.com Alex Andrews Director of Operations aa@neuroscientific.com w w w. n e u r o s c i e n t i f i c . c o m 12

NeuroScientific Biopharmaceuticals — ShareCafe Small Cap "Hidden Gems" Webinar (December 2021) on 6ix